sm-tsp-2
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 4, 2015 (NCT02337855)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Schistosoma mansoniImmunity, active
Schistosoma mansoni immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sm-tsp-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03910972 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Baylor University, George Washington University, Makerere University |
| NCT03110757 | Phase 1 | Jun 29, 2017 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02337855 | Phase 1 | Feb 4, 2015 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2015 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| George Washington University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Makerere University | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1